Peptide Initiative

Peptide Mythbuster · Myth #005

BIG PHARMA DOESN'T SELL PEPTIDES

The billion-dollar blind spot in this argument

Verdict: BUSTED

01 / The claim

What people say

If peptides actually worked, pharmaceutical companies would be selling them — the fact that they don't proves peptides are just snake oil.Skeptic talking point

02 / Evidence

The data

Each point of evidence assessed against the original claim.

Refutes

Ozempic Revenue

Novo Nordisk's semaglutide products generated $21 billion in 2023. It's a 31-amino-acid peptide.

Refutes

Mounjaro Sales

Eli Lilly's tirzepatide hit $5.2 billion in its first full year. Also a peptide.

Refutes

FDA Approvals

Over 80 peptide drugs have received FDA approval. Dozens more in clinical trials.

Neutral

Patent Strategy

Pharma companies aggressively patent peptide modifications to maintain market exclusivity.

Neutral

Compounding Threat

Shortage declarations allowed compounders to produce semaglutide — pharma lobbied to end this.

Refutes

Price Differential

Branded Ozempic costs $900-1000/month. Compounded semaglutide ran $150-300 during shortages.

Refutes

Market Growth

Global peptide therapeutics market projected to exceed $90 billion by 2030.

03 / Verdict

The ruling

BUSTED

Pharmaceutical companies generate tens of billions annually from peptide drugs. The argument collapses under the weight of Ozempic alone.

04 / Key facts

The science

  1. 01$50+ BILLION ANNUALLYCombined GLP-1 peptide drug revenue in 2023. Pharma doesn't ignore molecules that print money.
  2. 0280+ APPROVEDFDA-approved peptide drugs currently on market, treating diabetes, cancer, osteoporosis, and more.
  3. 03INSULIN IS A PEPTIDEThe most prescribed drug in diabetes history is a 51-amino-acid peptide. Discovered 1921. Still selling.
  4. 04COMPOUNDING WARSPharma's fight isn't against peptides — it's against anyone else making them affordably.

05 / Deep dive

Why it matters

Peptide therapeutics represent one of pharma's fastest-growing sectors. GLP-1 agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are peptide drugs generating over $50 billion in combined annual revenue. The real tension isn't whether peptides work — it's whether compounding pharmacies can offer similar molecules outside the patent-protected pricing structure.

06 / Sources

References

  1. Trends in peptide drug discoveryMuttenthaler M, King GF, Adams DJ, Alewood PF (2021). Nature Reviews Drug Discovery. View source
  2. GLP-1 physiology informs the pharmacotherapy of obesityDrucker DJ (2022). Molecular Metabolism. View source
  3. Annual Report 2023Novo Nordisk (2024). Novo Nordisk Corporate Filing. View source
  4. Therapeutic peptides: current applications and future directionsWang L, et al. (2022). Signal Transduction and Targeted Therapy. View source
  • GLP-1
  • pharma
  • economics
  • compounding
  • semaglutide

Peptide Mythbuster. Evidence-based analysis.